Drugs / ALT-2074
ALT-2074
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00491543 | Jun 2007 → May 2008 | coronary artery disorder, type 2 diabetes mellitus | Synvista Therapeutics, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00320502 | May 2006 → Mar 2008 | acute coronary syndrome, type 2 diabetes mellitus | Synvista Therapeutics, Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00782613 Comparator | Nov 2008 → Mar 2009 | psoriasis | Synvista Therapeutics, Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT-2074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00491543 ↗ |
| Known as | 4,4-dimethyl-benziso-2H-selenazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00782613 ↗ |
| Known as | BXT-51072 | “ALT-2074 (BXT-51072) belongs to a class of drugs called "glutathione peroxidase mimics."” NCT00491543 ↗ |
| Known as | SYI 2074 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297259 ↗ |
| Modality | Other / unclassified | “BXT-51072 belongs to a class of drugs called "glutathione peroxidase mimics."” NCT00320502 ↗ |
| Modality | Small molecule | — CHEMBL4297259 ↗ |
| Route | Topical | “ALT-2074 will be applied topically twice daily” NCT00782613 ↗ |